Supported by The Suzhou Medical Center,No.Szlcyxzx202103;The National Natural Science Foundation of China,No.82171828;The Key R and D Plan of Jiangsu Province(Development of Social),No.BE2021652;The Subject Construction Support Project of The Second Affiliated Hospital of Soochow University,No.XKTJHRC20210011;The Wu Jieping Medical Foundation,No.320.6750.2021-01-12;The Special Project of"Technological Innovation"Project of CNNC Medical Industry Co.Ltd,No.ZHYLTD2021001;The Suzhou Science and Education Health Project,No.KJXW2021018;Foundation of Chinese Society of Clinical Oncology,No.Y-pierrefabre202102-0113 and No.Y-XD202002/zb-0015;The Beijing Bethune Charitable Foundation,No.STLKY0016;The Research Projects of China Baoyuan Investment Co.Ltd,No.270004;The Suzhou Gusu Health Talent Program,No.GSWS2022028;The Open Project of State Key Laboratory of Radiation Medicine and Protection of Soochow University,No.GZN1202302;The New Medical Technology Project of the Second Affiliated Hospital of Soochow University,No.23zl001;The Multi-center Clinical Research Project for Major Diseases in Suzhou,No.DZXYJ202304;The Postgraduate Research and Practice Innovation Program of Jiangsu Province,No.SJCX24_1814;The Gusu Health Talent Research Fund,No.GSWS2022053;The National Natural Science Foundation of China,No.82102824;The Scientific Research Program for Young Talents of China National Nuclear Corporation。
BACKGROUND Bone is a major site of metastasis in nasopharyngeal carcinoma(NPC).Recently,nuclear factor kappa-beta ligand(RANKL)inhibitors have garnered attention for their ability to inhibit osteoclast formation and b...
supported by the National Natural Science Foundation of China(Grant No.82372381,52071277);the National Natural Science Foundation of Zhejiang Province(Grant No.LY23H060013).
Repair of large bone defects remains to be clinically challenging,yet current bone repair strategies focus on optimizing the osteogenic capacity of bone grafts,while the role of osteoclasts in bone regeneration has be...
supported by Odense University Hospital’s Fund for Free Research (A5111);the Region of Southern Denmark’s Fund for Free Research (A955);the VELUX Foundations (VELUX25723);supported by the Novo Nordisk Foundation。
Denosumab is a monoclonal anti-RANKL antibody that inhibits bone resorption,increases bone mass,and reduces fracture risk.Denosumab discontinuation causes an extensive wave of rebound resorption,but the cellular mecha...
Introduction:Medication-related osteonecrosis of the temporal bone is rare and has been reported to be associated with the use of anti-resorptive and biologic agents.Here,we present the first case of tyrosine-kinase i...
Supported by The Shanghai Municipal Health Commission Clinical Research Project,No.202140140.
BACKGROUND For patients with acute paraplegia caused by spinal giant cell tumor(GCT)who require emergency decompressive surgery,there is still a lack of relevant reports on surgical options.This study is the first to ...
BACKGROUND Denosumab inhibits the receptor activator of nuclear factor kappa-ligand.It markedly increases bone mineral density and has been proven to reduce the risk of fractures.However,numerous adverse effects,notab...
BACKGROUND Calcitriol-induced hypercalcemia has been rarely reported in cases of lung cancer;however,it is frequently reported in cases of lymphoid malignancy and granulomatous disease.We present a rare case of hyperc...
BACKGROUND Administering anti-osteoporotic agents to patients perioperatively is a widely accepted approach for improving bone fusion rates and reducing the risk of complications.The best anti-osteoporotic agents for ...
The current study evaluated the efficacy and safety of a denosumab biosimilar,QL1206(60 mg),compared to placebo in postmenopausal Chinese women with osteoporosis and high fracture risk.At 31 study centers in China,a t...